These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29100409)

  • 41. Antisense modulation of IL7R splicing to control sIL7R expression in human CD4
    Galarza-Muñoz G; Kennedy-Boone D; Schott G; Bradrick SS; Garcia-Blanco MA
    RNA; 2022 Aug; 28(8):1058-1073. PubMed ID: 35613883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor.
    Scharner J; Qi S; Rigo F; Bennett CF; Krainer AR
    Mol Ther Nucleic Acids; 2019 Jun; 16():313-325. PubMed ID: 30965276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability.
    McNally EM; Wyatt EJ
    J Clin Invest; 2016 Apr; 126(4):1236-8. PubMed ID: 26999602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A framework for individualized splice-switching oligonucleotide therapy.
    Kim J; Woo S; de Gusmao CM; Zhao B; Chin DH; DiDonato RL; Nguyen MA; Nakayama T; Hu CA; Soucy A; Kuniholm A; Thornton JK; Riccardi O; Friedman DA; El Achkar CM; Dash Z; Cornelissen L; Donado C; Faour KNW; Bush LW; Suslovitch V; Lentucci C; Park PJ; Lee EA; Patterson A; Philippakis AA; Margus B; Berde CB; Yu TW
    Nature; 2023 Jul; 619(7971):828-836. PubMed ID: 37438524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.
    Aupy P; Echevarría L; Relizani K; Goyenvalle A
    Biomedicines; 2017 Dec; 6(1):. PubMed ID: 29271929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aberrant RNA Splicing in Cancer and Drug Resistance.
    Wang BD; Lee NH
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of Tak1 alternative splicing by splice-switching oligonucleotides.
    Zhou D; Shao Q; Fan X; Wu P; Lin W; Wei H; He F; Jiang Y
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1018-1024. PubMed ID: 29475001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transcriptome profiling reveals the high incidence of hnRNPA1 exon 8 inclusion in chronic myeloid leukemia.
    Li SQ; Liu J; Zhang J; Wang XL; Chen D; Wang Y; Xu YM; Huang B; Lin J; Li J; Wang XZ
    J Adv Res; 2020 Jul; 24():301-310. PubMed ID: 32405436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RNA splicing process analysis for identifying antisense oligonucleotide inhibitors with padlock probe-based isothermal amplification.
    Ren X; Deng R; Wang L; Zhang K; Li J
    Chem Sci; 2017 Aug; 8(8):5692-5698. PubMed ID: 28989608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of TDP-43 induces synaptic dysfunction that is rescued by
    Keuss MJ; Harley P; Ryadnov E; Jackson RE; Zanovello M; Wilkins OG; Barattucci S; Mehta PR; Oliveira MG; Parkes JE; Sinha A; Correa-Sánchez AF; Oliver PL; Fisher EMC; Schiavo G; Shah M; Burrone J; Fratta P
    bioRxiv; 2024 Jun; ():. PubMed ID: 38979232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetics: TKI resistance: finding the crack in the BIM.
    Villanueva MT
    Nat Rev Clin Oncol; 2012 Apr; 9(5):247. PubMed ID: 22473101
    [No Abstract]   [Full Text] [Related]  

  • 52. Intrathecal administration of antisense oligonucleotide against p38α but not p38β MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice.
    Luo X; Fitzsimmons B; Mohan A; Zhang L; Terrando N; Kordasiewicz H; Ji RR
    Brain Behav Immun; 2018 Aug; 72():34-44. PubMed ID: 29128611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs.
    Liang XH; Nichols JG; Sun H; Crooke ST
    Nucleic Acids Res; 2018 Jan; 46(1):293-313. PubMed ID: 29165591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Function of serine/arginine-rich splicing factors in hematopoiesis and hematopoietic malignancies.
    Zhang H; Zhu H; Peng H; Sheng Y
    Cancer Cell Int; 2024 Jul; 24(1):257. PubMed ID: 39034387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development and validation of AI/ML derived splice-switching oligonucleotides.
    Fronk AD; Manzanares MA; Zheng P; Geier A; Anderson K; Stanton S; Zumrut H; Gera S; Munch R; Frederick V; Dhingra P; Arun G; Akerman M
    Mol Syst Biol; 2024 Jun; 20(6):676-701. PubMed ID: 38664594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic Targeting of RNA Splicing in Cancer.
    Bonner EA; Lee SC
    Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How Driver Oncogenes Shape and Are Shaped by Alternative Splicing Mechanisms in Tumors.
    Wojtyś W; Oroń M
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RNA splicing dysregulation and the hallmarks of cancer.
    Bradley RK; Anczuków O
    Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
    Sahin I; George A; Seyhan AA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
    Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.